Gene Therapy for Duchenne Muscular Dystrophy: Advances and Considerations

Strategic Insights -

A recent research review from McGill University has shed light on the efficacy and safety of delandistrogene moxeparvovec in treating Duchenne muscular dystrophy (DMD). The study, financed by the American Academy of Neurology (AAN), evaluated six clinical trials, including four with peer-reviewed data available. The research team found that delandistrogene moxeparvovec showed promise in improving muscle function and reducing disease symptoms in DMD patients.

Key Takeaways:

  • The study reviewed available clinical trial data on delandistrogene moxeparvovec in patients with DMD, covering six clinical trials, including four with peer-reviewed data available.
  • 134 boys with DMD were exposed to delandistrogene moxeparvovec, with 128 being ambulatory and aged between 4 to 12.
  • The research concluded that additional clinical trials and real-world evidence collection are essential to establish the long-term effectiveness and benefits of delandistrogene moxeparvovec in treating DMD.
  • The authors evaluated the risk of bias using the American Academy of Neurology's 2017 therapeutic classification of evidence scheme, considering safety information, regulatory decisions, and clinical context.
  • Tracie Anne Caller, Julie A. Parsons, Laurent Servais, and other researchers from McGill University contributed to the study.
  • Delandistrogene moxeparvovec gene therapy has been recommended for use in individuals with DMD, but its long-term effectiveness requires further investigation.

Statistics:

  • 134 boys with DMD were exposed to delandistrogene moxeparvovec in the studied clinical trials.
  • 128 of the boys were ambulatory, and aged between 4 to 12.
  • 6 clinical trials were identified, which included 4 with peer-reviewed data available.
  • 2 of the 4 studies with available data were classified as Class I, while 2 were classified as Class III.
  • The research concluded that additional real-world evidence collection is essential to understand the long-term effectiveness and benefits of delandistrogene moxeparvovec in treating DMD.

Sources:

  • NewsRx. Research Data from McGill University Update Understanding of Gene Therapy (Delandistrogene Moxeparvovec Gene Therapy In Individuals With Duchenne Muscular Dystrophy: Evidence In Focus). Gene Therapy Weekly. June 19, 2025; p 387.
  • Delandistrogene Moxeparvovec Gene Therapy In Individuals With Duchenne Muscular Dystrophy: Evidence In Focus. Neurology, 2025;104(11).